Rhizoxin is a tubulin-binding cytotoxic compound, isolated from the fungus Rhizopus chinensis, with significant antineoplastic activity in several munrne and human tumour models (Tsuruo et al., 1986; Takahashi et al., 1987) . In a previous phase I study, the drug was administered by i.v. bolus injection at 3 week intervals. Twenty-four patients with refractory solid tumours were treated; 60 courses of rhizoxin were given, at doses ranging from 0.8 to 2.6 mg m-2. Grade 3 mucositis, grade 4 leucopenia and grade 3 diarrhoea were dose limiting but reversible at 2.6 mg m2, the maximum tolerated dose for both previously untreated and heavily pretreated patients. Alopecia and moderate discomfort at the injection site occurred at all doses. Other side-effects, including peripheral neuropathy, phlebitis and nausea and vomiting, were sporadic and mild. Two heavily pretreated patients with recurrent breast cancer had minor responses to rhizoxin, one at 1.6 mg m-2 and the other at 2.6 mg m-2. Plasma concentrations of rhizoxin were measured by high-performance liquid chromatography and showed considerable inter-subject variation in the plasma concentration-time profiles; the area under the curve ranged from 0.29 to 0.96 ;tg ml-' min-'. Rhizoxin has shown some clinical activity in the phase I study and a dose of 2.0 mg m2 administered by i.v. bolus every 3 weeks was recommended for phase II studies (Bissett et al., 1992 One patient who had received platinum-based chemotherapy previously had a partal response in a pelvic mass and para-aortic lymphadenopathy which was apparent after two cycles of chemotherapy with a duration of 3 months. No patients had a separate response using the CA125 criteria of the study.
Colorectal cancer Twenty patients with advanced colorectal cancer were entered in the study (Table I) . Two patients were ineligible because they did not fulfil the entry criteria and are not included for analysis. Seventeen of the 18 eligible patients received at least two courses of rhizoxin 2 mg m-2 at 3 weekly intervals. Fourteen of the 18 eligible patients were WHO performance status 0 or l. Four patients had more than three sites of disease. A total of 58 courses were given, with the mean number being three.
The most common toxicities were alopecia in 91l% of courses (gades 1 and 2); tiredness in 45% of courses (grade 3, 5%); lymphocytopenia in 38% of courses (grade 3, 9%) and stomatitis in 21% of courses (grade 3, 3% The results of these studies with only one partial response documented in ovarian cancer, suggests that at the tested schedule of 2mgm-2 administered by i.v. bolus every 3 weeks, rhizoxin has no clinically relevant anti-tumour activity in ovarian, colorectal or renal cancer. Similar patterns of toxicity were seen in each of the three groups of patients with moderate alopecia, lymphocytopenia and gastrointestinal toxicity as previously described in the phase I study (Bissett et al., 1992 
